Kornimate/medical-research-clean huggingface dataset:
improving motor stroke recovery using patient-tailored non-invasive brain stimulation

Conditions: Stroke

Summary: many individuals are often left with problems moving their arm and hand, months to even years after a stroke. recent progress in research suggests the application of non-invasive brain stimulation, such as transcranial direct current stimulation (tdcs), in conjunction with rehabilitation exercises can further improve a person's ability to move after stroke. however, the problem is that this doesn't work for everyone, and researchers do not know why. one reason may be that tdcs is currently applied using a one-size-fits-all approach. researchers apply the same type of tdcs to everyone, assuming the stroke affects everyone in the same way. but, researchers know this is not the case. for example, each person will likely have different amounts of damage to brain regions that control movements. a better understanding of how the stroke uniquely affects a person's brain will help us to know which is the correct type of tdcs to apply for that person. therefore, the objective of this research is to determine whether the amount of damage to brain regions that control movements can predict which type of tdcs will be more effective to help a person improve their ability to move. participants will undergo 1 session of magnetic resonance imaging, and three sessions of tdcs.


Eligibility criteria:
inclusion criteria: * unilateral first time stroke in middle cerebral artery territory * greater 3 months post-stroke * able to raise arm onto a table from a seated position exclusion criteria: * severe cognitive or comprehension deficits that may compromise informed consent or understanding of instructions * severe apraxia and neglect * neurodegenerative or psychiatric disease * contraindications to mri and tdcs (e.g. metal in head, pacemaker, claustrophobia)

Keywords: motor rehabilitation transcranial direct current stimulation
use of n-acetylcysteine (nac) in fingernail biting

Conditions: Onychophagia

Summary: to conduct a pilot randomized placebo-controlled feasibility trial of n-acetylcysteine (nac) in onychophagia, preliminarily assessing the tolerability and effects of this pharmacotherapy on young adults who bite their fingernails. it is proposed that nac will help decrease fingernail biting.

this is a proof-of-concept pilot placebo-controlled trial of n-acetylcysteine (nac) in young people who bite fingernails. the primary interest is in assessing the feasibility of conducting this line of research, while preliminarily exploring potential effects on nail biting, as measured by nail length.

Eligibility criteria:
inclusion criteria: * 1. age 18-30 2. fingernail biter for ≥5 years exclusion criteria: * 1. any unstable major dsm-iv axis i psychiatric disorder in the past month (e.g., psychotic disorders, bipolar disorder, major depressive disorder) 2. current substance dependence in the past month 3. current unstable major medical disorder or medical condition in the past 6 months (e.g., renal impairment) 4. current pregnancy or breastfeeding 5. current seizure disorder or asthma, due to possible elevated risk for adverse effects with nac in individuals with these conditions 6. known hypersensitivity to nac 7. use of carbamazepine or nitroglycerin (or any other medication deemed to be hazardous if taken with nac) within 14 days of study participation

Keywords: anxiety impulse control depression adhd fingernail biting n-acetylcysteine nac
prevalence of carbohydrate intolerance in lean and overweight/obese children

Conditions: Obesity; Type 2 Diabetes

Summary: the purpose of this study is to determine the prevalence of impaired glucose (carbohydrate) tolerance in lean children with a family history of diabetes and in overweight/obese children with or without a family history of diabetes mellitus.

the patient participates in the study for a total duration of approximately four hours. the study nurse will do a nursing assessment, including measuring the patient's height, weight, waist circumference, hip circumference, blood pressure, and pulse, along with evaluation of acanthosis nigricans and striae rubrae. the patient's percent body fat, fat mass and lean mass may also be measured using a tanita scale. the nurse will obtain a family and medical history from the patient and/or the patient's parent/guardian. in addition, before starting the oral glucose tolerance test (ogtt), the nurse will request a urine sample from the patient for analysis of microalbumin and creatinine. the patient will receive 1.75 g/kg to a maximum of 75 g of a sugar drink, orally (glucola). the patient will have one intravenous line. "emla" or a local anesthetic (0.1cc buffered lidocaine) will be applied before the placement of the iv catheter. blood will be drawn 10 times over three hours. should abnormal glucose results be found, appropriate referrals will be made. we will draw approximately 80 cc of blood during this study. the blood will be analyzed for glucose, lactate, insulin, proinsulin, c-peptide, interleukin-6, tumor necrosis factor-α(tnf), free fatty acids (ffas), enhanced lipid profile, leptin, and adiponectin as well as an optional 10 cc sample to be stored for future undetermined analysis.

Eligibility criteria:
inclusion criteria: * ages 7-21 * family history of type 2 diabetes mellitus exclusion criteria: * children will be excluded if they have previously been treated for another endocrinopathy or are on any chronic medications that are known to alter glucose or insulin metabolism, such as oral steroids, or certain psychiatric medications, such as xeleca, lithium and paxil. * lean (not overweight or obese) will be defined as a body mass index (bmi) (kg/m2) less than the 85th percentile specific for age and gender, overweight will be defined as a bmi between the 85th and 95th percentiles, and obesity will be defined as a bmi greater than the 95th percentile. * children will be excluded from participating in the genetic analysis if they are treated oral glucocorticoids or antirejection or chemotherapy (e.g. tacrolimus, lasparaginase.

Keywords: obesity type 2 diabetes
effectiveness of trigger point dry needling on plantar fasciitis

Conditions: Plantar Fascitis

Summary: plantar fasciitis could lead to pain, disability and impaired balance. dry needling that targets myofascial trigger points (mtrps) has been shown to be beneficial in reducing pain, improving range of motion and function in patients with musculoskeletal conditions. previous systematic review suggested a positive effect of dry needling on improving pain intensity and pain-related disability in patients with plantar heel pain (llurda-almuzara et al., 2021). however, the generalisability of the result is limited by small number of trials and heterogenicity in the dry needling application. also, there is currently no evidence on its effect on dynamic balance and ankle dorsiflexion range of motion. this randomized controlled trial is designed to investigate the effectiveness of dry needling on pain, pain-related disability, dynamic balance and ankle dorsiflexion range of motion in patients with plantar fasciitis.

twenty participants aged 18 - 65 years with plantar fasciitis will be recruited and randomized to (1) dry needing and stretching exercise group or (2) stretching exercise group, receiving three treatment sessions over three weeks. the primary outcome measure will be numeric pain rating scale (nprs) and the secondary outcome measures will be chinese foot and ankle outcome score (faos), modified star excursion balance test (msebt) and weight bearing lunge test (wblt) measured at baseline and week 4.

Eligibility criteria:
inclusion criteria: * age of 18-65 years * clinical diagnosis of plantar fasciitis in accordance with the clinical guidelines of the orthopaedic section of the american physical therapy association (apta) * pain intensity of a minimum score of 5 on 11-point nprs * presence of trigger points of the gastrocnemius or soleus muscles or both * history of plantar heel pain for over 1 month exclusion criteria: * needle allergy or phobia * bleeding disorders or severe vascular disease * pregnancy * cancer * fracture or surgery in the foot region or leg * infection * dermatological disease in the area of needling * history of injection therapy in the heel during the previous three months * cognitive impairment * neurological disorders affecting balance

Keywords: plantar fasciitis dry needling
the relationship between fapi results and myocardial fibrosis after acute myocardial infarction

Conditions: Acute Myocardial Infarction (AMI)

Summary: fapi is a new method to discover the fibrosis of cardiac myocardium in some conditions, like myocardial infarction or cardiomyopathy. this purpose of this study is to find the relationship between fapi results and myocardial fibrosis through some clinical serum inflammatory factors level. meanwhile, it is the first time to provide the prognostic value of fapi in the progression of acute myocardial infarction.


Eligibility criteria:
inclusion criteria: acute myocardial infarction 1) after the successful primary intervention ;2) normal ef value; - exclusion criteria: acute myocardial infarction 1) primary pci failure; 2) ef reduced; 3) death during the hospitalization; -
efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

Conditions: Diabetic Kidney Disease

Summary: the purpose of this study was to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.


Eligibility criteria:
inclusion criteria: * men or women ≥18 years of age * subjects with type type 2 diabetes mellitus as defined by the american diabetes association * diagnosis of diabetic kidney disease with persistent high albuminuria or persistent very high albuminuria at the run-in and screening visit * pretreated with either angiotensin-converting enzyme inhibitor (acei) or angiotensin receptor blocker (arb) at maximal tolerated labeled dose without adjustments * serum potassium \<=4.8 mmol/l exclusion criteria: * confirmed significant non-diabetic renal disease, including clinically relevant renal artery stenosis * uncontrolled arterial hypertension (ie, mean sitting systolic blood pressure (sbp) ≥170 mmhg or mean sitting diastolic blood pressure(dbp) ≥110 mmhg at run in visit, or mean sitting sbp ≥160 mmhg or mean sitting dbp ≥100 mmhg at screening) * clinical diagnosis of chronic heart failure with reduced ejection fraction (hfref) and persistent symptoms {new york heart association (nyha) class ii - iv} at run in visit \[class 1a recommendation for mineralcorticoid receptor antagonist (mras)\] * dialysis for acute renal failure within 12 weeks of run-in visit * renal allograft in place or scheduled kidney transplant within next 12 months * glycated hemoglobin (hba1c) \>12%

Keywords: type 2 diabetes kidney diseases
dexpramipexole and cimetidine drug drug interaction (ddi)

Conditions: Amyotrophic Lateral Sclerosis

Summary: this study will assess the effect of cimetidine on the pharmacokinetics (pk) of dexpramipexole in healthy volunteer and evaluate the safety and tolerability of dexpramipexole when given with or without cimetidine. additionally, this study will explore the influence of genetic variation on the pk of dexpramipexole when given with or without cimetidine.

this is a single-center, open-label, randomized, two-period, crossover study in approximately 14 healthy subjects. the goals of this study are as follows: to assess the effect of cimetidine on the pharmacokinetics (pk) of dexpramipexole in healthy volunteers. to evaluate the safety and tolerability of dexpramipexole when given with or without cimetidine. to explore the influence of genetic variation on the pk of dexpramipexole when given with or without cimetidine.

Eligibility criteria:
inclusion criteria: * subjects who, in the opinion of the investigator, are healthy as determined by medical history, physical examination, and 12 lead ecg * adult males/females aged 18 to 55 years inclusive * male and female subjects of childbearing potential must practice effective contraception during the study and up to 90 days after their last dose. exclusion criteria: * history of malignant disease, including solid tumors and hematologic malignancies. * history of clinically significant endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, and renal, or other major diseases, as determined by the investigator. * treatment with prescription medication and/or over-the-counter products and herbal-containing and/or alternative health preparations and procedures. * surgery within 90 days prior to check-in.
sleep quality in mechanically ventilated patients

Conditions: Respiratory Failure

Summary: patients requiring mechanical ventilation in the icu will undergo three consecutive nights of polysomnography to record sleep patterns while receiving three modes of mechanical ventilation; proportional assist ventilation (pav), pressure support ventilation (psv), assist control ventilation (acv), applied in random order. the purpose is to determine the effect of mode of mechanical ventilation on patient-ventilator asynchrony and sleep quality.


Eligibility criteria:
inclusion criteria: * age 18-75 * received mechanical ventilation \>72 hours * glasgow coma scale \>10 * acute physiology score \<13 * ready for partial ventilatory support: intact respiratory drive, pao2/fio2 ratio \>200 on positive end expiratory pressure (peep) less than or equal to 5 cmh2o, and ph of 7.35 to 7.45 * sedation: analgesia at dose not higher than 0.01 mg/kg/hr morphine equivalent x 48 hours, sedation at dose not higher than 0.01 mg/kg/hr lorazepam equivalent x 72 hours. * anticipate ongoing need for partial ventilatory support for the following 72 hours exclusion criteria: * successful completion of spontaneous breathing trial * neurological injury, encephalopathy or abnormal eeg * history of central sleep apnea * general anaesthesia within 72 hours from study entry * requiring haloperidol \>10 mg/24 hours * hemodynamically unstable * sepsis

Keywords: pav (proportional assist ventilation); sleep; polysomnography; mechanical ventilation
hpv serum level and fdg pet ct in patients with cervical cancer treated with radical radiochemotherapy

Conditions: Cervical Cancer

Summary: the main purpose of the study is to describe changes in plasma hpv dna levels in patients with locally advanced cervical cancer during radical radiochemotherapy (crt) and to correlate changes with response to treatment. monitoring of the response to treatment will also be assessed in fdg pet ct imaging.

ninety-five per cent of cervical cancer cases are caused by persistent infections with carcinogenic hpvs. locally advanced stage ib2 to iva cervical cancers are treated with definitive chemoradiation therapy (crt). despite known clinical prognostic factors of poor treatment outcome such as advanced stage and positive nodal status, we still don't know predictors of relapse. hpv status will be assessed in the neoplastic tissue and dna from the blood serum of patients with cervical cancer will be isolated and analyzed by real-time pcr. plasma hpv dna would identify patients with residual disease after crt due to persistent detectable hpv. this would earlier detect high risk patients who would benefit from adjuvant therapy. while metabolic response in post - therapy fdg pet ct is predictive of survival, there is usually 3 months waiting period time needed to perform this imaging. this pilot study will provide preliminary estimates of the correlation between plasma hpv dna level, pet finding and clinical outcome in polish cervical cancer patients.

Eligibility criteria:
inclusion criteria: age limits: more than 18y histologically confirmed squamous cell carcinoma, figo stage ib-iva planned for radical radiochemotherapy eastern cooperative oncology group (ecog) performance status 0,1,2 exclusion criteria: patients who have received any anticancer treatment for their cervical cancer. eastern cooperative oncology group (ecog) performance status \> 2 other cervical cancer tumor histologies (e.g. small cell, serous) contraindications to 18fdg pet-ct contraindication to radiochemotherapy known pregnancy or lactating

Keywords: locally advanced cervical cancer hpv radiochemotherapy fdg pet ct
music intervention for brain-heart disease in myotonic dystrophy type 1 (dm1)

Conditions: Myotonic Dystrophy, Congenital; Myotonic Dystrophy, Type 1 (DM1); Myotonic Dystrophy Type 1; Myotonic Dystrophy Type 1 (DM1)

Summary: the goal of this interventional study is to demonstrate the feasibility and tolerability of dalcroze music intervention for children with congenital dm1, while providing indications of its effectiveness in improving brain and heart symptoms of dm1. additionally, information from the collection of biological samples and wearable devices (accelerometer, eeg headband and ecg chest strap) will be used to identify brain-heart biomarkers and outcome measures for use in future research and trials. researchers will compare the results of physical and cognitive assessments for each participant to assessments from baseline after 10 weeks of weekly music sessions. qualitative measures (questionnaires and focus groups) will inform the feasibility of this intervention for this population. the main questions this study aims to answer are: * are weekly music education sessions feasible for children with dm1? * are weekly music education sessions tolerable for children with dm1? participants will: * attend 45-minute-long music sessions once weekly for 10 weeks. * attend two clinic visits for cognitive and physical assessments. * provide blood, saliva, stool and urine samples. * use wearable devices both at-home and during music sessions. * parents/caregivers of participants will complete questionnaires and participate in three focus groups.


Eligibility criteria:
inclusion criteria: * participants between the ages of 6 to 18 with genetically confirmed congenital or infantile-onset myotonic dystrophy type 1 (dm1). * participants willing to stay on stable medication from the day of screening to end of study. exclusion criteria: * insufficient english language skills to complete required assessments and questionnaires. * participant is non-verbal. * failure to provide signed informed consent by participant or designated decision maker (i.e. parent, legal guardian or power of attorney). * failure to provide signed informed consent by parents/caregivers for dyad participation. * participant is not a resident of canada, due to risk of attrition. * patients for whom - in the opinion of the investigator - it would not be safe to participate in the study.

Keywords: music intervention myotonic dystrophy dm1 rare disease dalcroze music education
etascai pilot project

Conditions: Cognition; Affect (Mental Function); Inflammation

Summary: this pilot study aims to investigate the chronic effects of etas® on cognitive, affective and inflammatory outcomes in healthy adults aged 60-80 years with mild to moderate subjective cognitive complaints.

this pilot study will employ a double-blind, randomised, placebo-controlled parallel design to investigate the chronic effects of 12-week-long etas® consumption on affective, inflammatory, metabolic, and anthropometric outcomes in healthy older adults with mild to moderate subjective cognitive complaints. thirty participants will be randomised to intervention 1, intervention 2, or placebo groups where they will be consuming capsules containing 300mg etas®, 1500mg etas®, or placebo, respectively, for 12-weeks. outcome measures will be acquired before and after a 12-week chronic supplementation. these will include cognitive measures of overall cognitive functioning, executive function, and cognitive failures; affective measures of depression and anxiety symptomatology; quality of life, and sleep; gastrointestinal symptomatology; inflammatory measures of ifn-γ, il-1β, il-2, il-4, il-6, il-8, il-10, il-12p70, il-13, tnf-α, crp; systolic and diastolic blood pressure, as well as height, weight, hip and waist circumference. in addition, tau from plasma will be recorded at all timepoints.

Eligibility criteria:
inclusion criteria: * aging between 60-80 years old * having normal vision and hearing * having a body mass index between 18.5 and 30 * having mild to moderate subjective cognitive complaints exclusion criteria: * smoking * having food allergies or intolerances * following restrictive and/or unbalanced diets * changing dietary intake majorly in past month * being diagnosed with any psychiatric or neurologic conditions (e.g. schizophrenia, depression, dementia) including eating disorders * being diagnosed with any cardiometabolic diseases (including type ii diabetes and cardiovascular disease), or suffering from hypertension or thrombosis related disorders or suffer from thyroid disease * being anaemic * currently taking anticoagulants, antiplatelet medication, antidepressants, proton-pump inhibitors * currently consuming prebiotic or probiotic supplements * continuous antibiotic use for \> 3 days within 1 month prior to enrolment * continuous use of weight-loss drug for \> 1 month before screening * having inflammatory bowel disease; coeliac disease; total colectomy or bariatric surgery; irritable bowel disease; end stage renal disease; active cancer, or treatment for any cancer, in last 3 years

Keywords: etas® cognition depression anxiety sleep quality of life inflammation tau
dental erosion in patients with gastro-oesophageal reflux

Conditions: Dental Erosion

Summary: not only caries but also exposure to acids can lead to loss of tooth structure. this acid-related tooth structure loss is defined as dental erosion. a relationship between dental erosion and occurence of reflux disease was shown in numerous studies. on the one hand, patients with dental erosions frequently show reflux disease. on the other hand, many - but not all - reflux patients show dental erosions. it is believed that certain salivary parameters might explain, why not all reflux patients alike are affected of dental erosions. the aim of this study is to analyze the relationship and the extent of occurrence of dental erosions and reflux symptoms, including investigation of certain salivary parameters.


Eligibility criteria:
inclusion criteria: * patients who are treated at the clinic for gastroenterology and gastrointestinal oncology and have a 24-hours ph monitoring or impedance measurement performed for medical reasons exclusion criteria: * inability to give written consent * age \<18 years * intake of proton pump inhibitors (ppis) if they are not discontinued at least one week before study participation